Hikma’s management was keen to emphasize the growth potential for its other slate of portfolios and businesses after the company’s US authorized generic version of Jazz Pharmaceuticals’ Xyrem (sodium oxybate) 0.5g/ml oral solution soared above expectations in 2023, driving the London-listed firm’s annual Generics sales up by two-fifths to $937m, on the back of an admittedly “tough” 2022.
Moving into 2024, Hikma will step up significantly the royalties it will pay Jazz for the product. The firm debuted the product at the beginning of 2023, with a six-month exclusivity period and much more favorable royalties
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?